Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $29.22, for a total transaction of $66,972.24. Following the completion of the sale, the chief executive officer directly owned 137,500 shares in the company, valued at $4,017,750. This trade represents a 1.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Berndt Modig also recently made the following trade(s):
- On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $28.60, for a total transaction of $65,551.20.
- On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42.
Pharvaris Price Performance
NASDAQ:PHVS opened at $29.45 on Thursday. The firm has a 50 day simple moving average of $28.32 and a 200-day simple moving average of $26.73. The firm has a market cap of $1.93 billion, a PE ratio of -9.26 and a beta of -2.34. Pharvaris N.V. has a 1-year low of $15.46 and a 1-year high of $33.33.
Hedge Funds Weigh In On Pharvaris
Several institutional investors and hedge funds have recently bought and sold shares of PHVS. Geode Capital Management LLC increased its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after purchasing an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Legal & General Group Plc increased its position in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the last quarter. Amundi increased its position in shares of Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares in the last quarter.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Wolfe Research assumed coverage on shares of Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Citizens Jmp dropped their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.18.
Check Out Our Latest Report on Pharvaris
Pharvaris Company Profile
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Stories
- Five stocks we like better than Pharvaris
- The Palantir Paradox—Record Numbers and a Stock That Won’t Cooperate
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
